Key result
SGLT2 inhibitors and finerenone reduce heart failure events and kidney progression across diverse patient groups.
Why the study?
Cardiorenal syndrome is common in older adults and carries increased mortality, while geriatric syndromes such as delirium, falls, or functional decline can obscure classical signs of congestion and the most severely frail remain underrepresented in trials.
This narrative review outlines a practical, frailty-adapted framework combining cardiological, nephrological, and geriatric evidence for diagnosing and managing cardiorenal syndrome in adults aged 65 years and older.
Answers are grounded in this paper and cite their sources.
CRS warrants consideration in older HF patients with atypical symptoms; leaves open optimal diagnostic and therapeutic approaches.
Heart failure and chronic kidney disease (CKD) coexist so often in older adults that cardiorenal syndrome (CRS) is a common phenotype in geriatric practice, with renal impairment carrying a graded increase in mortality. On a substrate of cardiovascular and renal ageing, venous congestion and neurohormonal activation link the two organs, while delirium, falls or functional decline may obscure the classical signs of congestion. Lung and venous ultrasound, age-stratified natriuretic peptide thresholds and creatinine–cystatin C equations can support diagnosis when physical signs are unreliable. Sodium–glucose cotransporter 2 inhibitors reduce heart failure events across the ejection fraction spectrum and slow CKD progression, with consistent effects across age and frailty subgroups. Finerenone reduces kidney and cardiovascular events in albuminuric diabetic CKD; in heart failure with an ejection fraction of 40% or higher, it reduced worsening heart failure events without a significant kidney benefit. Natriuresis-guided decongestion, rapid up-titration of therapy after admission, intravenous iron and rehabilitation have been tested in trials enrolling many older patients, although the most severely frail remain underrepresented. Frailty-adapted prescribing and monitoring, deprescribing, shared decisions on dialysis or conservative care, and multidisciplinary models form the practical framework proposed in this narrative review of cardiological, nephrological and geriatric evidence in adults aged 65 years and older.
No takes yet. Share an insight, caveat, or question.
Soraci et al. (2026) conducted a review in Cardiorenal syndrome (heart failure and chronic kidney disease). SGLT2 inhibitors reduce heart failure events and slow CKD progression across age/frailty groups, while finerenone reduces worsening HF in HF with LVEF ≥40%.
Synapse has enriched 10 related papers. Consider them for comparative context: